An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2020-02-12
Target enrollment:
Participant gender:
Summary
This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil
diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203,
TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308. The study assessed the long term safety
of oral treprostinil and the effect of continued treatment with oral treprostinil on exercise
capacity after 1 year of treatment.